NCT01760863

Brief Summary

The primary purpose of this study is to compare the re-infection rates in patients undergoing 2-stage revision arthroplasty who receive additional oral antibiotic therapy to those patients who received in-hospital perioperative antibiotic only. Patients will be monitored for re-infection following hospital discharge, defined as deep infection of the joint space/capsule that requires return to the operating room within 24-months of the re-implantation procedure.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
185

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jul 2011

Longer than P75 for not_applicable

Geographic Reach
1 country

4 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2011

Completed
1.5 years until next milestone

First Submitted

Initial submission to the registry

January 2, 2013

Completed
2 days until next milestone

First Posted

Study publicly available on registry

January 4, 2013

Completed
7.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2020

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 23, 2020

Completed
Last Updated

August 25, 2021

Status Verified

August 1, 2021

Enrollment Period

9.1 years

First QC Date

January 2, 2013

Last Update Submit

August 19, 2021

Conditions

Keywords

RevisionKneeHipArthroplastyOralAntibioticsInfection

Outcome Measures

Primary Outcomes (1)

  • Infection Rate

    24 months

Study Arms (2)

Oral Antibiotics

EXPERIMENTAL

Oral antibiotics for 3 months; recommendation for antibiotics will be made by an infectious disease specialist.

Other: Oral Antibiotics

No oral antibiotics

NO INTERVENTION

No oral antibiotics.

Interventions

Oral Antibiotics will be prescribed for 3 months per recommendations of an infectious disease specialist.

Oral Antibiotics

Eligibility Criteria

Age18 Years - 90 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adult patients undergoing 2-stage revision arthroplasty of the knee or hip with the causative organism(s) identified using tissue culture and/or joint fluid analysis that is amenable to oral antibiotic therapy. Patients must be able to tolerate oral antibiotics and agree to participate in the study.

You may not qualify if:

  • Patients with a fungal prosthetic joint infection, unable to tolerate or refuse to undergo oral antibiotic therapy, unable to follow-up at the specified intervals, allergic to the therapy of preference, or have an organism that is not amenable to oral antibiotic therapy.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (4)

Rush University Medical Center

Chicago, Illinois, 60607, United States

Location

Central DuPage Hospital

Winfield, Illinois, 60190, United States

Location

Rothman Institute

Philadelphia, Pennsylvania, 19107, United States

Location

Vanderbilt

Nashville, Tennessee, 37232, United States

Location

Related Publications (1)

  • Zywiel MG, Johnson AJ, Stroh DA, Martin J, Marker DR, Mont MA. Prophylactic oral antibiotics reduce reinfection rates following two-stage revision total knee arthroplasty. Int Orthop. 2011 Jan;35(1):37-42. doi: 10.1007/s00264-010-0992-x. Epub 2010 Mar 7.

MeSH Terms

Conditions

Prosthesis-Related InfectionsInfections

Interventions

Anti-Bacterial Agents

Condition Hierarchy (Ancestors)

Postoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Anti-Infective AgentsTherapeutic UsesPharmacologic ActionsChemical Actions and Uses

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD

Study Record Dates

First Submitted

January 2, 2013

First Posted

January 4, 2013

Study Start

July 1, 2011

Primary Completion

August 1, 2020

Study Completion

September 23, 2020

Last Updated

August 25, 2021

Record last verified: 2021-08

Locations